TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07356453: A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

Sponsor: FoRx Therapeutics AG · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,193,808

Rescue Site Savings

+$785,400

Unlock Full NCT07356453 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07356453 Rescue Dossier →